BCL2L1 and melanoma: The tumor-intrinsic risk of recurrence in stage I–III melanomas can be classified with an immunohistochemical signature consisting of Bax, Bcl-X, PTEN, COX-2, β-catenin, MTAP, and CD20 (58–60).